1. Metabolic Enzyme/Protease
  2. HMG-CoA Reductase (HMGCR)

HMG-CoA Reductase (HMGCR)

HMG-CoA Reductase (HMGCR) is the rate-controlling enzyme of the mevalonate pathway, the metabolic pathway that produces cholesterol and other isoprenoids. Normally in mammalian cells this enzyme is suppressed by cholesterol derived from the internalization and degradation of low density lipoprotein (LDL) via the LDL receptor as well as oxidized species of cholesterol. Competitive inhibitors of the reductase induce the expression of LDL receptors in the liver, which in turn increases the catabolism of plasma LDL and lowers the plasma concentration of cholesterol, an important determinant of atherosclerosis. HMG-CoA reductase is thus the target of the widely available cholesterol-lowering drugs known collectively as the statins. HMG-CoA reductase is anchored in the membrane of the endoplasmic reticulum, and was long regarded as having seven transmembrane domains, with the active site located in a long carboxyl terminal domain in the cytosol.

HMG-CoA Reductase (HMGCR) Related Products (23):

Cat. No. Product Name Effect Purity
  • HY-17502
    Simvastatin Inhibitor >98.0%
    Simvastatin is a competitive inhibitor of HMG-CoA reductase with a Ki of 0.2 nM.
  • HY-N0504
    Lovastatin Inhibitor 99.47%
    Lovastatin, a HMG-CoA reductase inhibitor, is a cholesterol-lowering drug.
  • HY-17379
    Atorvastatin hemicalcium salt Inhibitor 99.98%
    Atorvastatin (hemicalcium salt) is a potent HMG-CoA reductase inhibitor with the IC50 value of 8 nM.
  • HY-17504
    Rosuvastatin Calcium Inhibitor
    Rosuvastatin Calcium is a competitive inhibitor of HMG-CoA reductase with IC50 of 11 nM.
  • HY-B0144
    Pitavastatin Calcium Inhibitor 99.94%
    Pitavastatin Calcium is a competitive inhibitor of the enzyme HMGCR (HMG-CoA reductase) results in a reduction in LDL cholesterol synthesis Target: HMG-CoA reductase Pitavastatin (usually as a calcium salt) is a member of the blood cholesterol lowering medication class of statins, marketed in the United States under the trade name Livalo.
  • HY-104051
    Monacolin J Inhibitor
    Monacolin J is an inhibitor of cholesterol biosynthesis, and inhibits the activity of HMG-CoA reductase.
  • HY-14664A
    Fluvastatin sodium Inhibitor >98.0%
    Fluvastatin sodium is a competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase (HMGCR), used to treat hypercholesterolemia and to prevent cardiovascular disease.
  • HY-17408
    Mevastatin Inhibitor 98.45%
    Mevastatin (Compactin; ML236B) inhibits HMGCR (HMG-CoA reductase) (Ki for acid form is 1 nM) which in turn inhibits isoprenoid biosynthesis and therefore blocks protein isoprenylation and reduces plasma cholesterol levels in humans.
  • HY-B0165A
    Pravastatin sodium Inhibitor 99.32%
    Pravastatin sodium is an HMG-CoA reductase inhibitor against sterol synthesis with IC50 of 5.6 μM.
  • HY-17640
    Nicodicosapent Inhibitor 98.19%
    Nicodicosapent is a fatty acid niacin conjugate that is also an inhibitor of the sterol regulatory element binding protein (SREBP), a key regulator of cholesterol metabolism proteins such as PCSK9, HMG-CoA reductase, ATP citrate lyase, and NPC1L1.
  • HY-13528
    Clinofibrate Inhibitor >98.0%
    Clinofibrate (S-8527) is a hypelipidemic agent and a HMG-CoA reductase inhibitor.
  • HY-17504S
    Rosuvastatin D6 Calcium Inhibitor 98.54%
    Rosuvastatin D6 Calcium is deuterium labeled Rosuvastatin, which is a competitive inhibitor of HMG-CoA reductase with IC50 of 11 nM.
  • HY-100793
    SR12813 Inhibitor 99.04%
    SR12813 is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, with an IC50 value of 0.85 μM.
  • HY-14664
    Fluvastatin Inhibitor
    Fluvastatin (Leschol) inhibits HMG-CoA reductase activity with IC50 of 8 nM.
  • HY-B0144A
    Pitavastatin Inhibitor
    Pitavastatin (NK-104) is a potent HMG-CoA reductase inhibitor, Pitavastatin inhibited cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in a human liver cancer cell line (HepG2).
  • HY-B0589
    Atorvastatin Inhibitor
    Atorvastatin is an inhibitor of HMG-CoA reductase used as a cholesterol-lowering medication that blocks the production of cholesterol.
  • HY-B0165
    Pravastatin Inhibitor
    Pravastatin is an HMG-CoA reductase inhibitor against sterol synthesis with IC50 of 5.6 μM.
  • HY-B0144AS
    Pitavastatin D4 Inhibitor
    Pitavastatin D4 is deuterium labeled Pitavastatin, which is a potent HMG-CoA reductase inhibitor.
  • HY-17504BS
    Rosuvastatin D3 Sodium Inhibitor
    Rosuvastatin D3 Sodium is deuterium labeled Rosuvastatin, which is a competitive inhibitor of HMG-CoA reductase with IC50 of 11 nM.
  • HY-B1189
    Meglutol Inhibitor
    Meglutol is an antilipemic agent which lowers cholesterol, triglycerides, serum beta-lipoproteins and phospholipids, and inhibits the activity of hydroxymethylglutarryl CoA reductases, which is the rate limiting enzyme in the biosynthesis of cholesterol.